Bushi Wang

发表

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

T. Steiner, E. Hylek, J. Eikelboom, 2017, The New England journal of medicine.

Idarucizumab for Dabigatran Reversal.

T. Steiner, E. Hylek, J. Eikelboom, 2015, The New England journal of medicine.

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

T. Steiner, E. Hylek, J. Eikelboom, 2015, Thrombosis and Haemostasis.

Design and rationale for the DIVERSITY study: An open‐label, randomized study of dabigatran etexilate for pediatric venous thromboembolism

L. Brandão, M. Brueckmann, M. Luciani, 2018, Research and practice in thrombosis and haemostasis.

Symptom and Quality of Life Improvement in LUX‐Lung 8, an Open‐Label Phase III Study of Second‐Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First‐Line Platinum‐Based Chemotherapy

E. Felip, J. Soria, S. Gadgeel, 2018, Clinical lung cancer.

Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705).

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2022, Clinical lung cancer.

Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design

L. Brandão, M. Brueckmann, M. Luciani, 2018, Research and practice in thrombosis and haemostasis.

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

William Pao, Gregory J Riely, D Ross Camidge, 2014, Cancer discovery.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

K. Syrigos, E. Felip, J. Soria, 2015, The Lancet. Oncology.

Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).

K. Syrigos, E. Felip, J. Soria, 2015 .

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.

H. Groen, W. Pao, E. Smit, 2017, Lung cancer.

Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.

K. Harrington, N. Gibson, A. Psyrri, 2019, JAMA oncology.

IDARUCIZUMAB FOR REVERSAL OF THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONS

T. Steiner, E. Hylek, J. Eikelboom, 2016 .

Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.

I. Bondarenko, M. Schuler, J. Yang, 2012 .

Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy.

J. Strausz, S. Ou, Keunchil Park, 2012 .

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

H. Groen, W. Pao, E. Smit, 2014, Cancer discovery.

Idarucizumab for Dabigatran Reversal.

T. Steiner, E. Hylek, J. Eikelboom, 2015, The New England journal of medicine.